1. Oxidative stress: A pivotal link among cardiovascular risk factors?

   • Bernard Waeber
   • François Feihl

   Invited Commentary Pages: 229 - 230

2. Web alert

   News Pages: 231 - 232

3. Clinical Trials Report

   • Michael A. Weber

   BriefCommunication Pages: 235 - 237

4. Clinical Trials Report

   • Helmy M. Siragy

   BriefCommunication Pages: 238 - 239

5. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-γ system

   • Michael L. Tuck

   OriginalPaper Pages: 240 - 243

6. Hypertension in black patients: Special issues and considerations

   • Shawna D. Nesbitt

   OriginalPaper Pages: 244 - 248

7. Differential effects of antihypertensive drugs on new-onset diabetes?

   • William J. Elliott

   OriginalPaper Pages: 249 - 256

8. Can we justify goal blood pressure of <140/90 mm hg in most hypertensives?

   • Raymond R. Townsend

   OriginalPaper Pages: 257 - 264

9. Treatment of multiple-risk patients: Using combination therapy to treat beyond LDL lowering

   • Howard S. Weintraub

   OriginalPaper Pages: 265 - 270

10. Clinical Trials Report

    • Domenic A. Sica

    BriefCommunication Pages: 273 - 274

11. Herbs and alternative therapies: Relevance to hypertension and cardiovascular diseases

    • Chaula K. Vora
    • George A. Mansoor

    OriginalPaper Pages: 275 - 280

12. Exercise and hypertension: Recent advances in exercise prescription

    • Linda S. Pescatello

    OriginalPaper Pages: 281 - 286

13. Angiotensin II-receptor antagonist in the treatment of hypertension

    • Massimo Volpe
    • Giuliano Tocci
    • Erika Pagannone

    OriginalPaper Pages: 287 - 293

14. Intermediate versus hard end points in clinical trials on hypertension

    • Guido Grassi

    OriginalPaper Pages: 294 - 297

15. Antihypertensive treatment and new-onset diabetes mellitus

    • Tonje Amb Aksnes
    • Henrik M. Reims
    • Giuseppe Mancia

    OriginalPaper Pages: 298 - 303